Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding
Join Thomas Schubert, CEO of 2bind, as he walks through experiments done on the Prometheus Panta to determine the optimal buffer for a vaccine candidate. This HIV-derived protein is used as an antigen target for vaccine development, and it is crucial that this target is stored in a buffer that reduces aggregation and enhances long-term stability. Learn how 2bind used Prometheus Panta to do a 96-condition buffer screen, find the optimal buffer for stability in standard and stressed conditions, and validate antibody binding to the antigen — all in one instrument.
